Review



aurora kinase inhibitor ii aki ii  (Santa Cruz Biotechnology)


Bioz Verified Symbol Santa Cruz Biotechnology is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Santa Cruz Biotechnology aurora kinase inhibitor ii aki ii
    (A) Varying concentrations of <t>AKi-II</t> were used to establish an EC 50 of <t>the</t> <t>inhibitor</t> in LNCaP and 22Rv1 PCa cells. (B) LNCaP PCa cells were treated with 10 μM AKi-II over 5 days and proliferation was measured via cell titre. (C) The effect pretreatment of LNCaP PCa cells with miR-331-3p has on the EC 50 concentration of Aki-II. (D) Effects on colony formation of LNCaP PCa cells between miR-NC/miR-331-3p treated cells vs miR-NC/miR-331-3p and AKi-II treated cells. (E) Effects of si-RALA treatment on colony formation between si-RALA treated vs si-RALA and AKi-II treated 22Rv1 PCa cells. *p<0.05; CI=0.95; n=3, Error bars = SD.
    Aurora Kinase Inhibitor Ii Aki Ii, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/aurora kinase inhibitor ii aki ii/product/Santa Cruz Biotechnology
    Average 86 stars, based on 1 article reviews
    aurora kinase inhibitor ii aki ii - by Bioz Stars, 2026-03
    86/100 stars

    Images

    1) Product Images from "miR-331-3p and Aurora Kinase inhibitor II co-treatment suppresses prostate cancer tumorigenesis and progression"

    Article Title: miR-331-3p and Aurora Kinase inhibitor II co-treatment suppresses prostate cancer tumorigenesis and progression

    Journal: Oncotarget

    doi: 10.18632/oncotarget.18664

    (A) Varying concentrations of AKi-II were used to establish an EC 50 of the inhibitor in LNCaP and 22Rv1 PCa cells. (B) LNCaP PCa cells were treated with 10 μM AKi-II over 5 days and proliferation was measured via cell titre. (C) The effect pretreatment of LNCaP PCa cells with miR-331-3p has on the EC 50 concentration of Aki-II. (D) Effects on colony formation of LNCaP PCa cells between miR-NC/miR-331-3p treated cells vs miR-NC/miR-331-3p and AKi-II treated cells. (E) Effects of si-RALA treatment on colony formation between si-RALA treated vs si-RALA and AKi-II treated 22Rv1 PCa cells. *p<0.05; CI=0.95; n=3, Error bars = SD.
    Figure Legend Snippet: (A) Varying concentrations of AKi-II were used to establish an EC 50 of the inhibitor in LNCaP and 22Rv1 PCa cells. (B) LNCaP PCa cells were treated with 10 μM AKi-II over 5 days and proliferation was measured via cell titre. (C) The effect pretreatment of LNCaP PCa cells with miR-331-3p has on the EC 50 concentration of Aki-II. (D) Effects on colony formation of LNCaP PCa cells between miR-NC/miR-331-3p treated cells vs miR-NC/miR-331-3p and AKi-II treated cells. (E) Effects of si-RALA treatment on colony formation between si-RALA treated vs si-RALA and AKi-II treated 22Rv1 PCa cells. *p<0.05; CI=0.95; n=3, Error bars = SD.

    Techniques Used: Concentration Assay

    (A) miR-NC and miR-331-3p (+/- AKi-II; 10μM) xenograft NSG mice were monitored over a 33 day period for tumor size and volume. (B) Coronal and axial images from Day 33 representative mice from miR-NC and miR-3313p (+/- AKi--II; 10μM) xenograft groups. Tumor area is highlighted by red dash circle. (C) End point Kaplan-Meier survival curve of 22Rv1 xenograft mice +/- miR-NC/ miR-331-3p /AKi-II; 10μM). Log-rank (Mantel-Cox) Test; ***p<0.0005. Logrank test for Trend p<0.0011.
    Figure Legend Snippet: (A) miR-NC and miR-331-3p (+/- AKi-II; 10μM) xenograft NSG mice were monitored over a 33 day period for tumor size and volume. (B) Coronal and axial images from Day 33 representative mice from miR-NC and miR-3313p (+/- AKi--II; 10μM) xenograft groups. Tumor area is highlighted by red dash circle. (C) End point Kaplan-Meier survival curve of 22Rv1 xenograft mice +/- miR-NC/ miR-331-3p /AKi-II; 10μM). Log-rank (Mantel-Cox) Test; ***p<0.0005. Logrank test for Trend p<0.0011.

    Techniques Used:



    Similar Products

    aurora kinase inhibitor ii aki ii  (Santa Cruz Biotechnology)
    86
    Santa Cruz Biotechnology aurora kinase inhibitor ii aki ii
    (A) Varying concentrations of <t>AKi-II</t> were used to establish an EC 50 of <t>the</t> <t>inhibitor</t> in LNCaP and 22Rv1 PCa cells. (B) LNCaP PCa cells were treated with 10 μM AKi-II over 5 days and proliferation was measured via cell titre. (C) The effect pretreatment of LNCaP PCa cells with miR-331-3p has on the EC 50 concentration of Aki-II. (D) Effects on colony formation of LNCaP PCa cells between miR-NC/miR-331-3p treated cells vs miR-NC/miR-331-3p and AKi-II treated cells. (E) Effects of si-RALA treatment on colony formation between si-RALA treated vs si-RALA and AKi-II treated 22Rv1 PCa cells. *p<0.05; CI=0.95; n=3, Error bars = SD.
    Aurora Kinase Inhibitor Ii Aki Ii, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/aurora kinase inhibitor ii aki ii/product/Santa Cruz Biotechnology
    Average 86 stars, based on 1 article reviews
    aurora kinase inhibitor ii aki ii - by Bioz Stars, 2026-03
    86/100 stars
    		  Buy from Supplier
    aurora kinase inhibitor ii (aki ii  (Millipore)
    90
    Millipore aurora kinase inhibitor ii (aki ii
    (A) Varying concentrations of <t>AKi-II</t> were used to establish an EC 50 of <t>the</t> <t>inhibitor</t> in LNCaP and 22Rv1 PCa cells. (B) LNCaP PCa cells were treated with 10 μM AKi-II over 5 days and proliferation was measured via cell titre. (C) The effect pretreatment of LNCaP PCa cells with miR-331-3p has on the EC 50 concentration of Aki-II. (D) Effects on colony formation of LNCaP PCa cells between miR-NC/miR-331-3p treated cells vs miR-NC/miR-331-3p and AKi-II treated cells. (E) Effects of si-RALA treatment on colony formation between si-RALA treated vs si-RALA and AKi-II treated 22Rv1 PCa cells. *p<0.05; CI=0.95; n=3, Error bars = SD.
    Aurora Kinase Inhibitor Ii (Aki Ii, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/aurora kinase inhibitor ii (aki ii/product/Millipore
    Average 90 stars, based on 1 article reviews
    aurora kinase inhibitor ii (aki ii - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    aurora kinase inhibitor ii (aki)  (Millipore)
    90
    Millipore aurora kinase inhibitor ii (aki)
    (A) Varying concentrations of <t>AKi-II</t> were used to establish an EC 50 of <t>the</t> <t>inhibitor</t> in LNCaP and 22Rv1 PCa cells. (B) LNCaP PCa cells were treated with 10 μM AKi-II over 5 days and proliferation was measured via cell titre. (C) The effect pretreatment of LNCaP PCa cells with miR-331-3p has on the EC 50 concentration of Aki-II. (D) Effects on colony formation of LNCaP PCa cells between miR-NC/miR-331-3p treated cells vs miR-NC/miR-331-3p and AKi-II treated cells. (E) Effects of si-RALA treatment on colony formation between si-RALA treated vs si-RALA and AKi-II treated 22Rv1 PCa cells. *p<0.05; CI=0.95; n=3, Error bars = SD.
    Aurora Kinase Inhibitor Ii (Aki), supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/aurora kinase inhibitor ii (aki)/product/Millipore
    Average 90 stars, based on 1 article reviews
    aurora kinase inhibitor ii (aki) - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) Varying concentrations of AKi-II were used to establish an EC 50 of the inhibitor in LNCaP and 22Rv1 PCa cells. (B) LNCaP PCa cells were treated with 10 μM AKi-II over 5 days and proliferation was measured via cell titre. (C) The effect pretreatment of LNCaP PCa cells with miR-331-3p has on the EC 50 concentration of Aki-II. (D) Effects on colony formation of LNCaP PCa cells between miR-NC/miR-331-3p treated cells vs miR-NC/miR-331-3p and AKi-II treated cells. (E) Effects of si-RALA treatment on colony formation between si-RALA treated vs si-RALA and AKi-II treated 22Rv1 PCa cells. *p<0.05; CI=0.95; n=3, Error bars = SD.

    Journal: Oncotarget

    Article Title: miR-331-3p and Aurora Kinase inhibitor II co-treatment suppresses prostate cancer tumorigenesis and progression

    doi: 10.18632/oncotarget.18664

    Figure Lengend Snippet: (A) Varying concentrations of AKi-II were used to establish an EC 50 of the inhibitor in LNCaP and 22Rv1 PCa cells. (B) LNCaP PCa cells were treated with 10 μM AKi-II over 5 days and proliferation was measured via cell titre. (C) The effect pretreatment of LNCaP PCa cells with miR-331-3p has on the EC 50 concentration of Aki-II. (D) Effects on colony formation of LNCaP PCa cells between miR-NC/miR-331-3p treated cells vs miR-NC/miR-331-3p and AKi-II treated cells. (E) Effects of si-RALA treatment on colony formation between si-RALA treated vs si-RALA and AKi-II treated 22Rv1 PCa cells. *p<0.05; CI=0.95; n=3, Error bars = SD.

    Article Snippet: Trichostatin A (TSA) (Cat #T-8552) and 5-aza-2’-deoxycytidine (AZA) (Cat #A-3656) were from Sigma and Aurora Kinase inhibitor II (AKi-II) was from Santa Cruz Biotech (Cat #SC-203827).

    Techniques: Concentration Assay

    (A) miR-NC and miR-331-3p (+/- AKi-II; 10μM) xenograft NSG mice were monitored over a 33 day period for tumor size and volume. (B) Coronal and axial images from Day 33 representative mice from miR-NC and miR-3313p (+/- AKi--II; 10μM) xenograft groups. Tumor area is highlighted by red dash circle. (C) End point Kaplan-Meier survival curve of 22Rv1 xenograft mice +/- miR-NC/ miR-331-3p /AKi-II; 10μM). Log-rank (Mantel-Cox) Test; ***p<0.0005. Logrank test for Trend p<0.0011.

    Journal: Oncotarget

    Article Title: miR-331-3p and Aurora Kinase inhibitor II co-treatment suppresses prostate cancer tumorigenesis and progression

    doi: 10.18632/oncotarget.18664

    Figure Lengend Snippet: (A) miR-NC and miR-331-3p (+/- AKi-II; 10μM) xenograft NSG mice were monitored over a 33 day period for tumor size and volume. (B) Coronal and axial images from Day 33 representative mice from miR-NC and miR-3313p (+/- AKi--II; 10μM) xenograft groups. Tumor area is highlighted by red dash circle. (C) End point Kaplan-Meier survival curve of 22Rv1 xenograft mice +/- miR-NC/ miR-331-3p /AKi-II; 10μM). Log-rank (Mantel-Cox) Test; ***p<0.0005. Logrank test for Trend p<0.0011.

    Article Snippet: Trichostatin A (TSA) (Cat #T-8552) and 5-aza-2’-deoxycytidine (AZA) (Cat #A-3656) were from Sigma and Aurora Kinase inhibitor II (AKi-II) was from Santa Cruz Biotech (Cat #SC-203827).

    Techniques: